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Background: Reported studies in the African population, on early pain relief in patients with acute 
abdominal pain are few. The objective of the study was to evaluate the effect of pentazocine (PZ) 
on pain relief, diagnostic accuracy and treatment decisions in patients with acute abdominal pain.                       
Methods: This was a prospective randomized clinical trial undertaken at the emergency 
department, Federal Medical Centre, Abeokuta. Seventy adult patients with acute abdominal pain 
were randomized to receive equal volumes intravenously, normal saline, (control group) or 
pentazocine 30mg (PZ group). Pain was measured with a standard 0 – 100mm Visual analogue 
scale (VAS). Pain score, diagnosis and treatment decision were recorded before and 60minutes 
after the injection. A VAS score change > 12mm was considered as clinically significant. Outcome 
measures were the differences in these parameters between the two study arms.                       
Results: Twenty patients in the PZ group and 9 patients in the control group had a VAS score drop 
>12mm. This difference is statistically significant. (X2= 6.56: p <0.02). In two patients pentazocine 
interfered with correct diagnosis and treatment. The initial decision to operate was deferred.                        
Conclusion: Pentazocine provided analgesia in patients with acute abdominal pain. Its 
administration caused delay in correct diagnosis and treatment in some patients. 
Introduction 
Reports of studies conducted in the Caucasian population and a critical appraisal of the aggregate weight 
of information contained in clinical trials published in the English literature suggest that early 
administration of analgesia to patients with acute abdominal pain is safe 1,2, 3,4,5,6.  One study reported 
some adverse outcomes in some patients7.However, in spite of these publications, evaluation of attitudes 
and practices of general surgeons in the United Kingdom and the United States of America in 1999 
revealed that 38- 67% believed that analgesia risks masking diagnostic findings 8.  
In the African population there are additional challenges faced by patients and doctors. These challenges 
include difficult access to, or non-availability of, narcotic analgesics in most of these countries, a scarcity 
of modern diagnostic tools and qualified medical specialists. Studies on this subject of early pain relief in 
adult patients with acute abdominal pain in the African population are few. We therefore decided to 
investigate the safety of early administration of pentazocine in adult patients with acute abdominal pain.    
Patients and Methods  
In this study, a clinical trial was designed to determine whether pentazocine administration achieved 
significant pain relief compared to a placebo, and whether pentazocine administration to patients with 
acute abdominal pain resulted in changes in physical findings, diagnostic accuracy and treatment 
decisions. Pentazocine was chosen because morphine is not readily available in most hospitals in the 
country. Pentazocine is an opioid analgesic, less potent than morphine. It acts by binding to opiate 
receptors in the central nervous system causing inhibition of ascending pain pathways thereby altering 
the perception of, and response to pain. Following intravenous injection, onset of action is 2-3 minutes 
and duration of action is 2-3 hours. Pentazocine is approved for use as an analgesic throughout the world. 
Its side effects include hypotension, dizziness, nausea and vomiting. It may be used as a premedication 
prior to anaesthesia.   
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This was a prospective randomized double blind placebo controlled trial that compared the effect of 
administration of 30mg of intravenous pentazocine against placebo (equal volume of 0.9%saline) on 
Emergency Department(ED) patients with acute abdominal pain (AAP). Endpoint measures were, pain 
relief, and changes in physical examination findings, diagnostic accuracy, and treatment decisions. The 
study was conducted in the emergency department of the Federal Medical Centre Abeokuta. This 
department treats over 10,000 adults annually. The study was approved by ethical review committee of 
the hospital. All patients provided informed consent.  
 Sample size: It was estimated that 70% of patients in the PZ group, and 30% of patients in the control 
group, would experience clinically significant drop in VAS score. These values were based on the earlier 
studies with morphine as the study drug6. With level of power at 80% and a 5% significance level, a 
sample size of 21 patients in each study arm, was obtained.              
Selection of participants: The study population was enrolled in a consecutive fashion during the study 
period. Patients were eligible if they were 18yrs or older, had non-traumatic abdominal pain of less than 
72 hours` duration and were judged by the attending physician to require surgical consultation. 
Excluded were patients who were pregnant, had systolic blood pressure of 90mm Hg and below, were not 
fully conscious, declined participation or were allergic to pentazocine. Hypotensive patients were 
excluded because the study drug may lower the blood pressure further. Patients who are not fully 
conscious may have a drop in the level of consciousness because the study drug acts by causing 
inhibition of some pathways in the central nervous system. 
Intervention and randomization: Seventy patients were randomized to receive 30mg pentazocine 
intravenously or an equal volume of normal saline solution administered as a single bolus. In view of the 
fact that identical vials were not available for the pentazocine and the placebo, randomization was done 
as follows: The E.D physician determined the eligibility of the patient. He enrolled him/her and obtained 
consent. He picked from a box, an opaque numbered sealed envelope, out of the 10 envelopes designed 
to enroll equal number to pentazocine and placebo. There were seven batches of such envelopes. 
He gave the envelope to a nurse who administered the study medication. The envelope number was 
recorded on the patient’s case note. A register matching the envelope number with drug assignment was 
kept in a location unknown to the investigators. The opened envelope with its content was dropped into 
another locked box kept in the E.D for that purpose. 
Methods of Measurements: The measurements were taken by medical officers working in the surgery 
department. One medical officer takes the measurements before and 60minutes after administration of the 
trial drug, unaware of whether it was pentazocine or placebo. The medical officer asked patient to rate 
his/her pain intensity on a standard horizontal 100mm VAS ranging from, O for no pain, to 100 for worst 
possible pain. The VAS has been shown to be a valid and reliable instrument for measurement of acute 
abdominal pain in E.D patients10. After this, the medical officer performed a clinical examination and 
recorded the following:       
a. provisional diagnosis and differential diagnosis (2 items only),  
b. area of tenderness if any, using the nine quadrants of the abdomen as reference,  
c.  provisional disposition of the patient, that is whether patient, definitely requires surgery, 
or definitely does not require surgery or is borderline.  
He then left the patient while the drug was administered and returned 60minutes later to repeat and record 
the VAS score and clinical findings on a fresh sheet of paper. The patient was then off the study and was 
treated as was the practice in the hospital. However all the patients are admitted for observation for a 
minimum of 24 hours.  Final diagnosis and final disposition were obtained from the patient’s hospital 
records usually within 14days. Non specific abdominal pain was entered for patients, who after 
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laboratory or/and radiological investigation had no apparent cause for the pain. A VAS score change of at 
least 13mm was considered as clinically significant11. Pearson’s chi square tests were done. A p-value < 
0.05 was considered significant.   
Results                                                                                                                                                                                     
Out of the 70 patients randomized, 5 patients allocated to the placebo group and 3 patients allocated to 
the PZ group were disqualified for incomplete records. Thirty-two patients received PZ while 30 patients 
received normal saline. Sixty-two patients were available for analysis. The characteristics of the study 
population are shown in Table 1.Twenty patients (62.5%) in the PZ group had a VAS score drop >12mm 
compared to nine patients (30%) in the control group. This was statistically significant (p <0.02). Two 
patients in the control group had an increase in the VAS score of 4mm and 3mm post injection.    
Table 1. Characteristics of the study population 
Parameters                                                                          PZ NS (control) 
Mean age in years (range ) 35 (21-52) 37 (19 -56) 
Proportion of female (no)                           56.3% (18) 60% (18) 
Initial VAS score Mean +/- SD (mm)                                       81 +/- 12   78 +/- 11 
Post injection VAS score (Mean mm)                                        53    69 
Mean VAS score change (mm)                                                       28    9 
No of patients with VAS score drop > 12mm                         20 (62.5%)  9 (30%) 
Table 2. Final diagnoses for Control and PZ Groups: 
Diagnosis  PZ (n=32) Control (n= 
30)    
                                                            No        (%) No         (%) 
Appendicitis                                                       9       (28.1) 6           (20) 
Peptic ulcer disease                                            3        (9.3) 6           (20) 
Primary peritonitis                                              2        (6.3) 2          (6.7) 
Pelvic inflammatory disease                               4       (12.5) 5         (16.7) 
Hepatoma                                                            0        (0) 2           (6.7) 
Colon obstruction                                                1       (3.15) 1           (3.3) 
Food poisoning/enteritis                                      3        (9.3) 1           (3.3) 
Degenerating fibroid                                           0        (0) 1           (3.3) 
Omental cyst                                                       1       (3.15) 0             (0) 
Abdominal wall hernia                                       5       (15.6) 2          (6.7) 
Non specific abdominal pain                              1       (3.15) 3           (10) 
Intestinal obstruction                                          1       (3.15) 1           (3.3) 
Ovarian cyst                                                        2         (6.3) 0              (0) 
Total                                                                    32      (100) 30         (100) 
Table 3. Clinically Important Differences Between Pre Injection, Post Injection and Final Diagnoses 
Pre injection diagnosis      Post injection diagnosis       Final diagnosis                         Allocation 
Gastritis                             Peptic ulcer disease             Gastritis                                   pentazocine  
Gaseous distension            Paralytic ileus                      Ileus (dm*)                                    control 
Appendicitis                       Ovarian cyst                       Appendicitis                            Pentazocine 
Enteritis                              Appendicitis                       Enteritis                                          Control 
Ovulation related pain        Appendicitis                      Ovulation related pain                    Control 
Bowel obstruction               Gastritis                            Bowel obstruction (cb**)         Pentazocine 
Peritonitis                            Ruptured appendicitis      10 peritonitis (dm*)                          Control 
Key: dm= diabetes mellitus, cb = congenital band. 10 = Primary  
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Table 4. Provisional and final disposition by allocation group                             
                                     Pentazocine (no=32)                                             Control (no= 30) 
                                     Provisional         Final                                      Provisional           Final 
For surgery                      15                     17                                             12                      13 
Not for surgery                  7                     15                                               7                      17 
Uncertain                         10                                                                      11                       
Changes in physical findings: In between the two examinations, there was a  slight change in severity of 
tenderness in 11 out of 32 patients (34.4%) in the PZ group, and 12 out of 30 (40%) of the control. The 
pre and post injection diagnoses were the same in these cases. There was complete disappearance of 
tenderness in 2 patients in the PZ group and in 1 patient in the control group. The pre injection diagnoses 
of mesenteric adenitis and appendicitis in the PZ group were changed to post injection diagnoses of 
nonspecific abdominal pain.  One patient in the control group had a diagnosis of acute appendicitis 
changed to gastroenteritis. Over the subsequent 24hrs, while these patients were under observation, the 
tenderness did not return.  
Diagnostic accuracy: The diagnostic accuracy in the PZ group was 90.6%. Three patients had a post-
injection diagnosis that was different from the final diagnosis Table 3.  Two patients, one with 
appendicitis and the other with bowel obstruction due to bands, had post injection diagnoses of right 
ovarian cyst pain and gastritis respectively due to reduction in the severity of pain and abdominal 
tenderness.  
While under observation the need for surgery was recognized and they were operated upon. They were 
provisionally allocated to the group not requiring surgery. Surgery was however delayed for 10hours and 
12hours respectively. The diagnostic accuracy in the control group was 86.7%. Four patients in the 
placebo group had a more serious provisional diagnosis and were provisionally allocated to require 
surgery Table 3 When results of investigations became available final diagnoses were made and surgery 
was avoided. The patients received antibiotic combinations as part of the treatment of the initial 
diagnosis.  
Final disposition: In all, 53.1% of the PZ group and 43.3% of the controls had surgery. These figures 
were comparable to 46 %( PZ) and 40 % (control) in the provisional disposition. The final diagnosis is 
shown in Table 2. 
Complications: A drop in blood pressure to less than 90mm Hg occurred in 7 patients, 5 patients in the 
PZ group and 2 patients in the control group. They were treated with intravenous 0.9% saline solution. 
There was no mortality.  
Discussion 
In the last two decades several studies in the Caucasian population comparing morphine against placebo 
had been published, which support the early administration of analgesia to patients with acute abdominal 
pain1,2,4,10. However, in spite of these publications, evaluation of attitudes and practices of general 
surgeons in the United Kingdom and the United States of America in 1999 revealed that 38- 67% 
believed that analgesia risks masking diagnostic findings8. Studies on this subject in the African 
population are however few. 
In this study pentazocine was used in place of morphine because morphine is available in only very few 
hospitals in Nigeria. Pentazocine is readily available but has weaker analgesic effect. The main findings 
of this study are that pentazocine administration significantly reduces discomfort. Diagnostic accuracy 
and treatment decisions were adversely affected in two (6.25%) patients that received pentazocine.  The 
drop in VAS score of patients who received pentazocine was statistically significant when compared to 
the placebo. Twenty patients (62.5%) in the PZ group had a VAS score drop >12mm compared to nine 
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patients (30%) in the control group (P<0.02). This result is comparable to results from previous studies 
using morphine as the study drug1,2. However two patients in the PZ group, one with appendicitis and the 
other with bowel obstruction due to bands, had post injection diagnoses of right ovarian cyst and gastritis 
respectively due to reduction in the severity of pain and abdominal tenderness. While under observation 
the need for surgery was recognized and they were operated upon and recovered fully. They were 
provisionally allocated to the group not requiring surgery. Surgery was however delayed for 10 hours and 
12 hours respectively. If the first surgical consultation was after the PZ injection such patient could be 
discharged from surgical service and might be treated as outpatient. The patient’s clinical condition will 
deteriorate and he will be worse off at subsequent presentation later. 
The situation is further compounded by lack of modern diagnostic tools such as CT scan and 
laparoscopic facilities which could aid diagnosis, in poor resource countries like Nigeria. In such 
countries every bit of physical finding counts. A second surgical consultation will also be required in a 
setting where the small number of experienced doctors is already overworked.      
Limitation of study 
Diagnostic suspicion bias. This form of detection bias could be introduced by the use of a physician who 
had already examined the patient before administration of the study drug. In such a before-after setting, 
the clinical information obtained from an initial examination before the administration of the study drug 
may be carried forward. This might bias findings acquired from a second examination by the same 
individual after administration of the study drug. However, the advantage of the two examinations being 
conducted by the same individual is the elimination of inter-observer variation. The single examiner is 
expected to pick out differences between the two examinations, thereby serving as his control. 
Conclusion 
• Result of this study shows that pentazocine provides analgesia when administered to patients 
with acute abdominal pain. However the drug masked important physical signs in a small number 
of patients. This resulted in delays in surgical intervention with attendant risk of increased 
complications. Repeated consultation was required to ensure such patients came to no harm. 
Patients with abdominal pain severe enough to require pentazocine should be admitted for a 
minimum of 24hrs, as was done in this study.  
• The administration of this drug to patients prior to transfer to another hospital is not 
recommended. The temporary relief in discomfort may encourage the patient to go home rather 
than proceed to the next hospital.  
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